Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
3.
Insect Mol Biol ; 30(3): 241-252, 2021 06.
Article in English | MEDLINE | ID: mdl-33368728

ABSTRACT

In Drosophila melanogaster, ecdysis triggering hormone (ETH) is the key factor triggering ecdysis behaviour and promoting trachea clearance. However, whether ETH plays the dual roles in non-dipteran insects is unknown. In this survey, we found that Ldeth mRNA levels were positively correlated with circulating 20-hydroxyecdysone (20E) titers in Leptinotarsa decemlineata. Ingestion of an ecdysteroid agonist halofenozide or 20E stimulated the transcription of Ldeth, whereas RNA interference (RNAi) of ecdysteroidogenesis (LdPTTH or LdSHD) or 20E signalling (LdEcR, LdUSP or LdFTZ-F1) genes inhibited the expression, indicating ETH acts downstream of 20E. RNAi of Ldeth at the final instar stage impaired pupation. More than 80% of the Ldeth-depleted beetles remained as prepupae, completely wrapped in the old larval cuticles. These prepupae became withered, dried and darkened gradually, and finally died in soil. The remaining Ldeth hypomorphs pupated and emerged as abnormal adults, bearing smaller and wrinkle elytrum and hindwing. Moreover, the tracheae in the Ldeth hypomorphs were full of liquid. We accordingly proposed that the failure of trachea clearance disenabled air-swallowing after pupa-adult ecdysis and impacted wing expansion. Our results suggest that ETH plays the dual roles, initiation of ecdysis and motivation of trachea clearance, in a coleopteran.


Subject(s)
Benzoates/administration & dosage , Coleoptera/growth & development , Ecdysterone/administration & dosage , Hydrazines/administration & dosage , Molting/physiology , RNA Interference , Animals , Ecdysterone/antagonists & inhibitors , Insecticides/administration & dosage , Larva/growth & development , Pupa/growth & development
4.
Eur Rev Med Pharmacol Sci ; 24(12): 7122-7130, 2020 06.
Article in English | MEDLINE | ID: mdl-32633407

ABSTRACT

OBJECTIVE: Acute liver injury (ALI) is mainly characterized by the symptom of metabolic disorders, homeostasis unbalance, and loss of liver function. There are no effective treatment methods at present stage except the liver transplantation. Effective treatment for early ALI is of great significance for the treatment of liver injury thereof. Glycyrrhizin (GL) is a promising inhibitor of the high-mobility group box-1 gene (HMGB1) which is expressed much higher in an inflammatory injury. However, it is not clear whether GL improves ALI via the inhibition of HMGB1. The present study is to probe the function and mechanism of glycyrrhizin on acute liver injury. MATERIALS AND METHODS: The expression of HMGB1 and inflammation in liver macrophages were analyzed. Lipopolysaccharide (LPS) was used in stimulating the macrophages to activate inflammatory response and recombined human HMGB1 was used to resist the function of GL to explore whether GL acted via the target of HMGB1. Then, LPS injection was utilized to induce ALI in mice, and then we evaluated GL treatment in ALI model. RESULTS: The results showed that the expressions of HMGB1 and inflammatory factors were markedly increased in LPS-activated liver macrophages. GL inhibited the progress of macrophages inflammation by restraining HMGB1, and the administration of GL could reverse the effects of LPS-induced ALI in mice. Moreover, PI3K/mTOR pathway was significantly suppressed by GL application. CONCLUSIONS: These results suggest that GL prevents inflammation in liver macrophages via inhibition of HMGB1. GL restrains inflammation and cell apoptosis by inhibiting HMGB1 via PI3K/mTOR signaling pathway in ALI. GL may become a novel drug for the therapy of ALI in the future.


Subject(s)
Apoptosis/drug effects , Chemical and Drug Induced Liver Injury/drug therapy , Glycyrrhizic Acid/pharmacology , Inflammation/drug therapy , Liver/drug effects , Phosphatidylinositol 3-Kinases/metabolism , Administration, Oral , Animals , Cells, Cultured , Chemical and Drug Induced Liver Injury/metabolism , Chemical and Drug Induced Liver Injury/pathology , Glycyrrhizic Acid/administration & dosage , HMGB1 Protein/antagonists & inhibitors , HMGB1 Protein/metabolism , Humans , Injections, Intraperitoneal , Lipopolysaccharides/administration & dosage , Lipopolysaccharides/pharmacology , Liver/metabolism , Liver/pathology , Macrophages/drug effects , Macrophages/metabolism , Male , Mice , Mice, Inbred C57BL , TOR Serine-Threonine Kinases/antagonists & inhibitors , TOR Serine-Threonine Kinases/metabolism
5.
Biotech Histochem ; 94(5): 374-380, 2019 Jul.
Article in English | MEDLINE | ID: mdl-30819007

ABSTRACT

KHC-4 is a 2-phenyl-4-quinolone analogue that exhibits anticancer activity. Aberrant activation of ß-catenin signaling contributes to prostate cancer development and progression. Therefore, targeting ß-catenin expression could be a useful approach to treating prostate cancer. We found that KHC-4 can inhibit ß-catenin expression and its signaling pathway in DU145 prostate cancer cells. Treatment with KHC-4 decreased total ß-catenin expression and concomitantly decreased ß-catenin levels in both the cytoplasm and nucleus of cells. KHC-4 treatment also inhibited ß-catenin expression and that of its target proteins, PI3K, AKT, GSK3ß and TBX3. We monitored the stability of ß-catenin with the proteasomal inhibitor, MG132, in DU145 cells and found that MG132 reversed KHC-4-induced proteasomal ß-catenin degradation. We verified CDK1/ß-catenin expression in KHC-4 treated DU145 cells. We found that roscovitine treatment reversed cell proliferation by arresting the cell cycle at the G2/M phase and ß-catenin expression caused by KHC-4 treatment. We suggest that KHC-4 inhibits ß-catenin signaling in DU145 prostate cancer cells.


Subject(s)
Antineoplastic Agents/therapeutic use , Morpholines/therapeutic use , Prostatic Neoplasms/metabolism , Quinolones/therapeutic use , beta Catenin/biosynthesis , Cell Cycle Checkpoints/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Humans , Male , Morpholines/metabolism , Prostatic Neoplasms/drug therapy , Quinolones/metabolism , Roscovitine/metabolism , Roscovitine/therapeutic use , Signal Transduction/drug effects
6.
Oncogene ; 37(5): 673-686, 2018 02 01.
Article in English | MEDLINE | ID: mdl-29035390

ABSTRACT

Urothelial carcinoma (UC) carcinogenesis has been hypothesized to occur through epigenetic repression of tumor-suppressor genes (TSGs). By quantitative real-time polymerase chain reaction array, we found that one potential TSG, angiopoietin-like 4 (ANGPTL4), was expressed at very low levels in all bladder cancer cell lines we examined. Previous studies had demonstrated that ANGPTL4 is highly expressed in some cancers, but downregulated, by DNA methylation, in others. Consequently, owing to these seemingly conflicting functions in distinct cancers, the precise role of ANGPTL4 in the etiology of UC remains unclear. In this study, using methylation-specific PCR and bisulfite pyrosequencing, we show that ANGPTL4 is transcriptionally repressed by DNA methylation in UC cell lines and primary tumor samples, as compared with adjacent noncancerous bladder epithelium. Functional studies further demonstrated that ectopic expression of ANGPTL4 potently suppressed UC cell proliferation, monolayer colony formation in vitro, and invasion, migration, and xenograft formation in vivo. Surprisingly, circulating ANGPTL4 was significantly higher in plasma samples from UC patients than normal control, suggesting it might be secreted from other cell types. Interestingly, our data also indicated that exogenous cANGPTL4 could promote cell proliferation and cell migration via activation of signaling through the Erk/focal adhesion kinase axis. We further confirmed that mouse xenograft tumor growth could be promoted by administration of exogenous cANGPTL4. Finally, immunohistochemistry demonstrated that ANGPTL4 was downregulated in tumor cells but overexpressed in tumor adjacent stromal tissues of muscle-invasive UC tissue samples. In conclusion, our data support dual roles for ANGPTL4 in UC progression, either as a tumor suppressor or oncogene, in response to microenvironmental context.


Subject(s)
Angiopoietin-Like Protein 4/genetics , Carcinoma, Transitional Cell/genetics , Epigenesis, Genetic/genetics , Gene Expression Regulation, Neoplastic/genetics , Tumor Microenvironment , Urinary Bladder Neoplasms/genetics , Aged , Aged, 80 and over , Angiopoietin-Like Protein 4/blood , Angiopoietin-Like Protein 4/metabolism , Animals , Carcinogenesis/genetics , Carcinoma, Transitional Cell/pathology , Carcinoma, Transitional Cell/surgery , Case-Control Studies , Cell Line, Tumor , Cell Movement/genetics , Cell Proliferation/genetics , Cystectomy , DNA Methylation/genetics , Down-Regulation , Female , Genes, Tumor Suppressor , Humans , Male , Mice , Mice, Inbred NOD , Mice, SCID , Middle Aged , Oncogenes/genetics , Promoter Regions, Genetic/genetics , Signal Transduction , Urinary Bladder/pathology , Urinary Bladder/surgery , Urinary Bladder Neoplasms/pathology , Urothelium/pathology , Xenograft Model Antitumor Assays
7.
Transplant Proc ; 49(1): 185-187, 2017.
Article in English | MEDLINE | ID: mdl-28104133

ABSTRACT

BACKGROUND: Liver transplantation in combination with chemotherapy in postoperative biliary rhabdomyosarcoma recurrence of children was evaluated. METHODS: An 8-year-old girl with biliary rhabdomyosarcoma underwent pancreatico-duodenectomy with postoperative vincristine (VCR), adriamycin (Act-D), and cyclophosphamide (CTX) (VAC chemotherapy) (VCR, 1 mg; Act-D, 0.7 mg; CTX, 1500 mg). Two years later, liver metastasis in the left and right lobes was found and was followed by VAC chemotherapy (CTX, 1800 mg; Act-D, 0.9 mg; VCR, 1.2 mg), with no change of the tumor size. One and a half years later, liver transplantation performed with postoperative pathology confirmed embryonal rhabdomyosarcoma recurrence and was followed by VAC chemotherapy (CTX, 1400 mg; Act-D, 0.7 mg; VCR, 1.9 mg) and immunosuppression treatment. RESULTS: The liver transplantation went well, with no major complications. At the time of this report, the patient had survived for 6 months, with a good quality of life and no tumor recurrence. CONCLUSIONS: For unresectable biliary rhabdomyosarcoma without extra-hepatic metastases, liver transplantation could be an effective treatment. Liver transplantation completely removes the tumor and reduces the long-term side effects of chemotherapy drugs.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biliary Tract Neoplasms/therapy , Liver Neoplasms/therapy , Liver Transplantation , Neoplasm Recurrence, Local/therapy , Rhabdomyosarcoma/therapy , Biliary Tract Neoplasms/pathology , Chemotherapy, Adjuvant , Child , Cyclophosphamide/therapeutic use , Dactinomycin/therapeutic use , Female , Graft Rejection/prevention & control , Humans , Immunosuppressive Agents/therapeutic use , Liver Neoplasms/secondary , Pancreaticoduodenectomy , Quality of Life , Rhabdomyosarcoma/secondary , Treatment Outcome , Vincristine/therapeutic use
8.
QJM ; 110(4): 255, 2017 Apr 01.
Article in English | MEDLINE | ID: mdl-28062746
9.
Int J Clin Pract Suppl ; (183): 53-62, 2015 May.
Article in English | MEDLINE | ID: mdl-26176181

ABSTRACT

AIM: The purpose of the study was to evaluate the impact of single nucleotide polymorphisms (SNPs) of Cytochrome P450 (CYP) 3A5 and adenosine triphosphate-binding cassette B1 (ABCB1) genotypes on TAC pharmacokinetics in Chinese paediatric patients. METHOD: A total of 136 Chinese paediatric liver recipients (R) and their donors (D) were divided into groups according to their CYP3A5 genotypes [expression of *1 allele: expressor (EX) or non-expressor (NEX)]. RESULT: Both recipient and donor CYP3A5*1 alleles had impacts on the TAC pharmacokinetics after liver transplantation. EX-R/EX-D recipients required a significantly higher TAC daily dose compared with NEX-R/NEX-D (0.24 ± 0.08 vs. 0.14 ± 0.06 mg/kg/day, p < 0.01). Age was also an independent factor on TAC requirement. Compared with EX-R/EX-D, non-expressor infants or recipients over 3-years old needed < 0.2 mg/kg/day. None of the ABCB1 SNPs (1236C>T, 2677G>A/T, 3435C>T) had an impact on TAC pharmacokinetics. However, EX-R/EX-D recipients bearing the ABCB1 1236-CC genotype required a much higher TAC dose than those without this genotype (0.23 vs. 0.18 mg/kg/day, p < 0.01), who required a similar TAC dose to that of NEX-R/NEX-D children. Furthermore, EX-R/EX-D with ABCB1 1236-CC recipients exhibited an markedly higher incidence of acute rejection and transplant-related infections clinically. CONCLUSION: CYP3A5 and ABCB1-1236 genotyping, in addition to recipient age, are necessary for establishing a more accurate TAC dosage regimen in paediatric liver recipients. We should be cautious regarding the treatment of paediatric recipients with both CYP3A5-expressor and ABCB1 1236-CC genotypes with TAC, as these patients are more susceptible to acute rejection and infection.


Subject(s)
Cytochrome P-450 CYP3A/genetics , DNA/genetics , Gene Expression Regulation , Graft Rejection/genetics , Liver Transplantation/adverse effects , Tacrolimus/administration & dosage , ATP Binding Cassette Transporter, Subfamily B/biosynthesis , ATP Binding Cassette Transporter, Subfamily B/genetics , Adult , Child, Preschool , China/epidemiology , Cytochrome P-450 CYP3A/biosynthesis , Dose-Response Relationship, Drug , Female , Follow-Up Studies , Genotype , Graft Rejection/drug therapy , Graft Rejection/epidemiology , Humans , Incidence , Infant , Male , Middle Aged , Polymerase Chain Reaction , Retrospective Studies , Time Factors , Young Adult
10.
Plant Biol (Stuttg) ; 15(1): 27-36, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23016572

ABSTRACT

In this work, the population of small RNAs (sRNAs) was studied in the gymnosperm Sequoia sempervirens during phase changes, specifically in the juvenile, adult and rejuvenated plants obtained in vitro. The potential target genes of Sequoia sRNAs were predicted through bioinformatics. Rejuvenation is a pivotal process in woody plants that enables them to regain their growth potential, which results in the recovery of physiologic and molecular characteristics that were lost when the juveniles mature into adult plants. The results from the five repeated graftings of juvenile, adult and rejuvenated plants in vitro showed that sRNAs could be classified into structural RNAs (Group I), small interfering RNAs (Group II), annotated microRNAs (Group III, and unannotated sRNAs (Group IV). The results indicate that only 573 among 15,485,415 sRNAs (Groups III and IV) had significantly different expression patterns associated with rejuvenation and phase change. A total of 215 sRNAs exhibited up-regulated expression patterns in adult shoots, and 358 sRNAs were down-regulated. Expression profiling and prediction of possible target genes of these unique small RNAs indicate possible functions in the control of photosynthetic efficiency and rooting competence abundance during plant rejuvenation. Moreover, the increase in SsmiR156 and decrease in SsmiR172 during plant rejuvenation suggested that these two microRNAs extensively affect phase transition.


Subject(s)
Gene Expression Regulation, Developmental/genetics , Plant Proteins/genetics , RNA, Plant/genetics , Sequoia/growth & development , Sequoia/genetics , Abscisic Acid/analysis , Abscisic Acid/metabolism , Biomass , Computational Biology , Epigenomics , Gene Expression Profiling , Gene Expression Regulation, Plant/genetics , Gene Library , High-Throughput Nucleotide Sequencing , MicroRNAs/genetics , MicroRNAs/metabolism , Molecular Sequence Annotation , Plant Growth Regulators/analysis , Plant Growth Regulators/metabolism , Plant Leaves/genetics , Plant Leaves/growth & development , Plant Leaves/physiology , Plant Roots/genetics , Plant Roots/growth & development , Plant Roots/physiology , Plant Shoots/genetics , Plant Shoots/growth & development , Plant Shoots/physiology , Plant Stems/genetics , Plant Stems/growth & development , Plant Stems/physiology , RNA, Plant/metabolism , RNA, Small Interfering/genetics , Sequoia/physiology , Up-Regulation/genetics
11.
Neuroscience ; 159(4): 1244-56, 2009 Apr 10.
Article in English | MEDLINE | ID: mdl-19409222

ABSTRACT

We previously demonstrated that ultra-low dose naloxone restores the antinociceptive effect of morphine in rats with pertussis toxin (PTX)-induced thermal hyperalgesia by reversing the downregulation of glutamate transporter (GT) expression and suppressing spinal neuroinflammation. In the present study, we examined the underlying mechanisms of this anti-inflammatory effect in PTX-treated rats, particularly on the expression of GTs. Male Wistar rats were implanted with an intrathecal catheter and, in some cases, with a microdialysis probe. All rats were injected intrathecally with saline (5 microl) or PTX (1 microg), then, 4 days later, were randomly assigned to receive a single injection of saline, ultra-low dose naloxone (15 ng), or the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580 (5 microg), followed by morphine injection (10 microg) 30 min later. Our results showed that PTX injection induced activation of microglia and a significant increase in P-p38 MAPK expression in the spinal cord. Ultra-low dose naloxone plus morphine significantly inhibited the effect of PTX on P-p38 MAPK expression in the spinal cord, while the p38 MAPK inhibitor SB203580 attenuated the PTX-induced mechanical allodynia, thermal hyperalgesia, increase in spinal cerebrospinal fluid excitatory amino acids, and downregulation of GTs. These results show that the restoration of the antinociceptive effect of morphine and GT expression in PTX-treated rats by ultra-low dose naloxone involves suppression of the p38 MAPK signal transduction cascade.


Subject(s)
Hyperalgesia/drug therapy , Morphine/administration & dosage , Naloxone/administration & dosage , Narcotic Antagonists/administration & dosage , Narcotics/administration & dosage , p38 Mitogen-Activated Protein Kinases/metabolism , Amino Acid Transport System X-AG/metabolism , Animals , Enzyme Inhibitors/administration & dosage , Excitatory Amino Acids/cerebrospinal fluid , Hyperalgesia/chemically induced , Imidazoles/administration & dosage , MAP Kinase Signaling System/drug effects , Male , Microglia/drug effects , Pertussis Toxin , Pyridines/administration & dosage , Random Allocation , Rats , Rats, Wistar , Spinal Cord/drug effects , Spinal Cord/metabolism , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors
12.
Endoscopy ; 38(10): 1024-8, 2006 Oct.
Article in English | MEDLINE | ID: mdl-17058168

ABSTRACT

BACKGROUND AND STUDY AIMS: Subepithelial tumors of the stomach used to be considered as benign, but they do have malignant potential, especially when they originate from the muscularis propria layer. The aims of this study were to determine the feasibility of endoscopic submucosal dissection (ESD) for the removal of subepithelial tumors from the muscularis propria layer and to evaluate the efficacy and safety of ESD for this indication. PATIENTS AND METHODS: A total of 12 lesions in 11 patients were eligible for inclusion in the study during the period between December 2004 and February 2006. ESD using an insulated-tip knife was used to remove gastric subepithelial tumors from the muscularis propria where this was possible. Endoscopic mucosal resection using a suction and cap method ("EMR-c") was used to obtain a sufficiently large specimen for tissue diagnosis if complete resection by ESD was not possible. RESULTS: Nine tumors were resected completely by ESD (success rate 75 %). The mean tumor size as determined by endoscopic ultrasound as 20.7 mm (range 6 - 40 mm). The histological diagnosis was gastrointestinal stromal tumor for eight lesions and leiomyoma for four tumors. The mean operation time was 60.9 minutes (range 20 - 170 minutes), and the average blood loss was 30 ml. No patient developed perforation or massive hemorrhage requiring surgical treatment, and there were no other immediate postprocedure complications. CONCLUSIONS: ESD can be used for the resection of intraluminal gastric subepithelial tumors and could replace treatment by surgical resection in some cases. EMR-c is an alternative method that can be used to obtain sufficient tumor tissue for histological diagnosis if complete resection by ESD fails.


Subject(s)
Endoscopy, Gastrointestinal/methods , Gastric Mucosa/surgery , Gastrointestinal Stromal Tumors/surgery , Leiomyoma/surgery , Stomach Neoplasms/surgery , Adult , Aged , Diagnosis, Differential , Endosonography , Female , Gastric Mucosa/diagnostic imaging , Gastric Mucosa/pathology , Gastrointestinal Stromal Tumors/diagnostic imaging , Gastrointestinal Stromal Tumors/pathology , Humans , Leiomyoma/diagnostic imaging , Leiomyoma/pathology , Male , Middle Aged , Neoplasm Staging , Retrospective Studies , Stomach Neoplasms/diagnostic imaging , Stomach Neoplasms/pathology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...